COEP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q2

FY2024Q3

FY2024Q4

-1.800

+1416.43%

-1.000

-78.26%

-0.800

-39.7%

Estimates Revision

The market is revising No Change the revenue expectations for Coeptis Therapeutics Holdings, Inc. (COEP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.50%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-12.50%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Coeptis Therapeutics Holdings Inc (COEP.O) is -4.31, compared to its 5-year average forward P/E of -16.84. For a more detailed relative valuation and DCF analysis to assess Coeptis Therapeutics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-16.84

Current PE

-4.31

Overvalued PE

21.93

Undervalued PE

-55.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.42

Current EV/EBITDA

-5.26

Overvalued EV/EBITDA

0.23

Undervalued EV/EBITDA

-5.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.41

Current PS

0.00

Overvalued PS

14.93

Undervalued PS

-6.11

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

COEP News & Events

Events Timeline

No data

News

8.5

01-06Globenewswire

Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.

7.0

2025-10-07Globenewswire

SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests

7.0

2025-10-07Globenewswire

URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP

People Also Watch

Frequently Asked Questions

What is Coeptis Therapeutics Holdings Inc (COEP) stock price today?

The current price of COEP is 14.14 USD — it has decreased -3.81 % in the last trading day.

What is Coeptis Therapeutics Holdings Inc (COEP)'s business?

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

What is the price predicton of COEP Stock?

Wall Street analysts forecast COEP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COEP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Coeptis Therapeutics Holdings Inc (COEP)'s revenue for the last quarter?

Coeptis Therapeutics Holdings Inc revenue for the last quarter amounts to 237.44K USD, decreased % YoY.

What is Coeptis Therapeutics Holdings Inc (COEP)'s earnings per share (EPS) for the last quarter?

Coeptis Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.58 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for Coeptis Therapeutics Holdings Inc (COEP)'s fundamentals?

How many employees does Coeptis Therapeutics Holdings Inc (COEP). have?

Coeptis Therapeutics Holdings Inc (COEP) has 5 emplpoyees as of January 09 2026.

What is Coeptis Therapeutics Holdings Inc (COEP) market cap?

Today COEP has the market capitalization of 78.50M USD.